Lilin Kenangan dipersembahkan untuk:
"Untuk orang yang tersayang.
papa, mama, kakak Ryan, adekku rezha.
Maafin aku selama Ini buat kalian kecewa. Aku belom bisa bahagiain kalian semua. Buat nama baik kerluarga jelek.
Aku sayang kalian semua
Untuk orang sesama seperti Kita. Hidup terus berjalan apapun pasrahkan semua yang mana pencipta. Kita orang2 terpilih yang bermental Baja. Setiap penyakit ada obatnya cuma di dunia Ini belom ada yang menemukan tapi Suatu saat pasti ada yang Menemukan. Kita di kasih seperti ini buat peleburan dosa. Kita beruntung bisa menebus dosa dulu sebelum menutup mata.
" oleh: Rinaldi
Urutkan berdasarkan: Judul (A\D) Tanggal (A\D) Nilai (A\D) Popularitas (A\D) Saat ini ditampilkan menurut: Judul (A - Z)
Pilot study for TB-HIV co-infection prevalence survey in Indonesia Deskripsi:Objective: To pilot and assess acceptability of unlinked anonymous testing and potential uptake of Voluntary Counselling and Testing (VCT) among tuberculosis (TB) patients in Jogjakarta, Indonesia and determine HIV prevalence among TB patients in the pilot area,
Method: We introduced unlinked anonymous HIV testing for TB patients attending Directly Observed Treatment, Short-course (DOTS) services between April-December 2006. Demographic characteristics were documented for all patients. Patients were additionally offered access to free VCT services. We used logistic regression to identify risk factors for HIV-positive test and for VCT non-interest.
There were 1681 TB patients registered during the study period. Out of these, 989 (58.8%) accepted and undertook unlinked anonymous testing. The acceptance rate of unlinked anonymous testing among those who were offered was 77.9%. There were no significant differences between the two groups apart from districts. HIV prevalence in all TB tested patients was 1.9 (95% CI 1.6-2.2). Out of those offered VCT, 856 (86.6%) were not interested.
Conclusion: The prevalence of HIV among TB patients is higher than WHO estimate for Indonesia. There was high acceptance rate to unlinked anonymous testing and low interest toward VCT.
Bila menginginkan file dapat diunduh dengan klik disini
Ukuran file: 0 bytes Dimasukkan: 30-Oct-2007 Downloand: 130
Self-reported side-effects of anti-retroviral treatment among IDUs: A 7-year longitudinal study Deskripsi:Abstract
The introduction of potent anti-retroviral treatment (ART) has transformed HIV disease into a chronic condition with the prospect, for the patient, of strict adherence to effective but life-long treatments. Within this framework, a major issue that can negatively affect adherence is the side-effects of the treatment. To date, studies documenting how individuals HIV-infected through drug injection (IDUs) experience ART-related side effects are sparse.
Longitudinal data collected from the APROCO-COPILOTE cohort have been used to compare the experience of ART-related side-effects who have been HIV-infected via injecting drug use and non-IDU patients. A 20-item list was used to collect self-reported side-effects over a 7-year follow up period.
Of 922 patients, 15% were IDUs. At any given visit, IDUs reported a signi?cantly higher number of side-effects and had approximately twice the risk of reporting any side effect than non-IDUs. Most commonly reported side-effects were dry skin, fatigue, vomiting, bone troubles, insomnia. After adjustment for social conditions, depressive symptoms, use of sleeping pills and time since HIV diagnosis, IDUs reported experiencing signi?cantly more side-effects than non-IDUs. Whether or not this is related to sensitivity to pain or to other comorbidities is dif?cult to establish.
Keywords: Side effects; Anti-retroviral treatment; HIV; Injecting drug users; Hyperalgesia; Pain Ukuran file: 0 bytes Dimasukkan: 28-Sep-2007 Downloand: 97
Universal access to HIV/AIDS treatment for injecting drug users: Keeping the promise Deskripsi: The introduction of highly active antiretroviral therapy (ART) in the mid-1990s brought new hope for people living with HIV/AIDS. ART promised to make a fatal disease a manageable chronic illness. In the early years access to such treatment was limited to those living in rich countries. The cost of medicines was prohibitive for most, the treatment regimens were complex with multiple side effects, treatment needed to be monitored by specialised physicians with access to sophisticated laboratories and other health services, and patients needed to be living in stable and supportive environments. Any belief that treatment was only feasible for the rich and privileged was shattered in 1997 when Brazil became the ?rst developing country to provide ART through its public health system.
Despite the leadership of Brazil few other developing countries (exceptions included such countries as Argentina, Botswana, Chile, Senegal, Uganda and Thailand) committed to a similar public health response thereafter. As HIV-related mortality and morbidity plummeted in most high-income countries with the rapid expansion of ART, ever-increasing numbers of people were dying in low-and middle-income countries. Such disparities in access to life-saving treatment galvanised a global movement in support of rapid treatment scale up. On 22 September 2003, the World Health Organization (WHO), the UNAIDS Secretariat, and The Global Fund to Fight AIDS, Tuberculosis and Malaria declared the lack of access to ART as a global health emergency. In response, WHO and the UNAIDS Secretariat announced a global target to provide ART to three million people in low-and middleincome countries by 2005, the “3 by 5” target. A multi-partner response followed in many countries, involving governments, civil society, technical agencies and donors. In the 2 years of the initiative those receiving ART in low-and middleincome countries increased from an estimated 400,000 at the end of 2003 to 1.3 million by the end of 2005 (WHO, 2006). The success of “3 by 5” did much to mobilise political commitment for treatment scale-up, leading to a declaration from G8 leaders in July 2005 to support countries to scale Ukuran file: 0 bytes Dimasukkan: 27-Sep-2007 Downloand: 95